Bizarre Patents
A method to tenderize meat with an explosive shockwave.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7402591 | Analgesic compositions containing buprenorphine An analgesic composition in parenteral unit dosage form or in a unit dosage form suitable for delivery via the mucosa comprising an amount of buprenorphine which is less than the clinical dose required to achieve pain relief and an amount of naloxone such that the r... | 07/22/2008 |
| 7255882 | Enkephalinase inhibitor and GABA precursor loading as anti-anxiety compositions Benzodiazepine withdrawal induced anxiety is treated by administration of an enkephalinase inhibitor, and a gamma-aminobutyric acid (“GABA”) precursor, or an endorphin or enkephalin releaser. These components promote restoration of normal neurotransmitter functi... | 08/14/2007 |
| 7157102 | Multi-layered microcapsules and method of preparing same A multi-layered microcapsule containing one or more active ingredients and process for preparing the same is disclosed. The multi-layered microcapsule comprises an inner solid microparticle core, typically composed of a biodegradable polymer, and having one or more ... | 01/02/2007 |
| RE39300 | Inhibiting the development of tolerance to and/or dependence on an addictive substance Nontoxic substances that block the N-methyl-D-aspartate (NMDA) receptor, e.g., a morphinan such as dextromethorphan or dextrorphan, or that block a major intracellular consequence of NMDA-receptor activation, e.g., a ganglioside such as GM1 or GT1b | 09/19/2006 |
| 7074833 | Use of the (1S,2R) enantiomer of milnacipran for the preparation of a drug A method for treating or preventing a disorder or a condition by double inhibition of serotonin (5-HT) and noradrenaline (NA) reuptake in a subject in need thereof, while limiting the risks of cardiovascular disturbances and/or organ and/or tissue toxicity, comprisi... | 07/11/2006 |
| 7041320 | High drug loaded injectable microparticle compositions and methods of treating opioid drug dependence Methods and compositions to induce opioid drug independence in opioid drug dependent individuals comprising administering opioid agonists and/or antagonists encapsulated in biodegradable polymer microspheres in a dosage formulation. ... | 05/09/2006 |
| 7026329 | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists This invention relates to a method for selectively enhancing the analgesic potency of a bimodally-acting opioid agonist such as morphine and simultaneously attenuating anti-analgesia, hyperalgesia, hyperexcitability, physical dependence and/or tolerance effects asso... | 04/11/2006 |
| 7005452 | Use of the dextrogyral enantiomer of milnacipran for the preparation of a drug The present invention concerns the use of a mixture of enantiomers enriched in the dextrogyral enantiomer of milnacipran and/or of at least one of its metabolites, as well as their pharmaceutically-acceptable salts, for the preparation of a drug intended to prevent ... | 02/28/2006 |
| 6995169 | Analgesic compositions containing buprenorphine An analgesic composition in parenteral unit dosage form or in a unit dosage form suitable for delivery via the mucosa comprising an amount of buprenorphine which is less than the clinical dose required to achieve pain relief and an amount of naloxone such that the r... | 02/07/2006 |
| 6849253 | Use of borate-polyol complexes in ophthalmic compositions Water-soluble borate-polyol complexes are useful as buffers and/or antimicrobials in aqueous ophthalmic compositions, including those containing polyvinyl alcohol. These compositions have greater antimicrobial activity than comparable compositions containing typical... | 02/01/2005 |
| 6828349 | Treatment of addiction and addiction-related behavior The present invention provides a highly efficient method for treating substance addiction and for changing addiction-related behavior of a mammal suffering from substance addiction. The method includes administering to a mammal an effective amount of gamma vinylGABA... | 12/07/2004 |
| 6699474 | Vaccine and immunserum against drugs of abuse Addictive drugs like cocaine, heroin or amphetamines are spreading in an epidemic manner in the western world and are an important factor in the spread of the acquired immune deficiency syndrome AIDS (multiple use of infected needles among drug addicts) t... | 03/02/2004 |
| 6696066 | Opioid agonist/antagonist combinations The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist ... | 02/24/2004 |
| 6686370 | Triazospiro compounds having nociceptin receptor affinity Disclosed are compounds of the formula (I) ##STR1## wherein A, R1, R2, R3, R4 and X1 are as disclosed herein. The compounds have affinity for the ORL1 receptor and are useful in the treatment of chron... | 02/03/2004 |
| 6653354 | NMDA antagonist comprising xenon The present invention relates to the use of xenon as a neuroprotectant and/or as an inhibitor of synaptic plasticity. In a preferred aspect, the xenon acts as an NMDA antagonist. The present invention also provides a method of reducing the level of activa... | 11/25/2003 |
| 6627635 | Method of preventing abuse of opioid dosage forms The invention relates in part to a method of reducing the abuse potential of an oral dosage form of an opioid analgesic, wherein an analgesically effective amount of an orally active opioid agonist is combined with an opioid antagonist into an oral dosage... | 09/30/2003 |
| 6617361 | Behavior chemotherapy A protocol for prevention of Alzheimer's disease onset is described. The protocol involves stimulating the implicit memory, followed by continuing such stimulation in conjunction with psychological treatments followed by continuing said stimulation of the... | 09/09/2003 |
| 6608064 | Pharmaceutical agents for the treatment of Parkinson's disease, ADHD and microadenomas The present invention is directed to the use of certain pyrido[1,2-a]-pyrazine derivatives, also described as bis-azabicyclic compounds and defined by the formula (I) herein, in the treatment of Parkinson's disease, attention deficit hyperactivity disorde... | 08/19/2003 |
| 6593367 | Treatment of addiction and addiction-related behavior The present invention provides a method for changing addiction-related behavior of a mammal suffering from addiction to a combination of abused drugs. The method includes administering to the mammal an effective amount of gamma vinylGABA (GVG) or a pharma... | 07/15/2003 |
| 6541520 | Treatment of addiction and addiction-related behavior The present invention provides a highly efficient method for treating substance addiction and for changing addiction-related behavior of a mammal suffering from substance addiction. The method includes administering to a mammal an effective amount of gamm... | 04/01/2003 |
| 6495155 | Injectable opioid partial agonist or opioid antagonist microparticle compositions and their use in reducing consumption of abused substances An injectable slow-release partial opioid agonist or opioid antagonist formulation is provided comprising a partial opioid agonist or opioid antagonist in a poly(D,L-lactide) excipient with a small amount of residual ethyl acetate. Upon intramuscular inje... | 12/17/2002 |
| 6492369 | Therapeutic agents for drug dependence A method for preventing or treating drug dependence comprising administering to a human in need thereof a pharmaceutically effective amount of a 1,4-(diphenylalkyl)piperazine compound represented by the following formula [I] or a pharmaceutically acceptab... | 12/10/2002 |
| 6475494 | Opioid agonist/antagonist combinations The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist ... | 11/05/2002 |
| 6468987 | Nutritional product for a person having ulcerative colitis An enteral nutritional product for a person having ulcerative colitis contains in combination (a) an oil blend which contains eicosapentaenoic acid (20:5n3) and/or docosahexaenoic acid (22:6n3), and (b) a source of indigestible carbohydrate which is metab... | 10/22/2002 |
| 6375957 | Opioid agonist/opioid antagonist/acetaminophen combinations The invention is directed in part to oral dosage forms comprising a combination of an opioid agonist, acetaminophen and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination prod... | 04/23/2002 |
| 6365636 | Use of borate-polyol complexes in ophthalmic compositions Water-soluble borate-polyol complexes are useful as buffers and/or antimicrobials in aqueous ophthalmic compositions, including those containing polyvinyl alcohol. These compositions have greater antimicrobial activity than comparable compositions contain... | 04/02/2002 |
| 6352984 | Olanzapine-N-oxide compositions and methods Methods and compositions are disclosed utilizing olanzapine-N-oxide for the treatment of psychosis in humans. Olanzapine-N-oxide exhibits a lessened liability toward drug-drug interactions than olanzapine and a more predictable dosing regimen than olanzap... | 03/05/2002 |
| 6333357 | Behavior chemotherapy A protocol for permanent modification of behavior and elimination of undesired habits is described. The protocol involves stimulating the implicit memory, followed by continuing such stimulation in conjunction with psychological treatments followed by con... | 12/25/2001 |
| 6306425 | Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol An injectable slow-release naltrexone formulation is provided comprising naltrexone in a poly(D,L-lactide) matrix with a small amount of residual ethyl acetate. Upon intramuscular injection of the composition, naltrexone is released in a controlled manner... | 10/23/2001 |
| 6288047 | Lipid-based immune modulator composition A method of treating an individual with an immune system with decreased activity by administering an effective amount of a lipid preparation derived from a natural source and enriched to contain at least 10% (w/w) phosphatidic acid (PA) is disclosed.... | 09/11/2001 |
| 6277384 | Opioid agonist/antagonist combinations The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist ... | 08/21/2001 |
| 6274633 | NMDA antagonist The present invention relates to the use of xenon as an NMDA antagonist. In particular, the invention relates to a method of treatment comprising modulating the activity of an NMDA receptor in a mammal, the method comprising modulating the activity of the... | 08/14/2001 |
| 6228863 | Method of preventing abuse of opioid dosage forms The invention relates in part to a method of reducing the abuse potential of an oral dosage form of an opioid analgesic, wherein an analgesically effective amount of an orally active opioid agonist is combined with an opioid antagonist into an oral dosage... | 05/08/2001 |
| 6204284 | Use of 1-(substitutedphenyl)-3-azabicyclo[3.1.0]hexanes for the treatment of chemical dependencies The invention is a method of treatment for the relief of an addictive, compulsive disorder which comprises the administration to a human or animal suffering from such a disorder an effective amount of the compound of the formula: ##STR1## wherein R i... | 03/20/2001 |
| 6203813 | Pharmaceutical delivery device and method of preparation therefor The present invention provides an opiate antagonist implant which is an admixture of an opiate antagonist, in either acid or base form, and a pharmaceutically acceptable carrier. The admixture is uniformly compressed into a subcutaneously implantable pell... | 03/20/2001 |
| 6197827 | Nicotine addiction treatment The present invention encompasses methods of treating patients for tobacco addiction and nicotine addiction, for palliating the effects of nicotine withdrawal, for providing or facilitating the effects of smoking cessation therapies and as long-term smoki... | 03/06/2001 |
| 6159963 | Method for treating substance abuse The invention provides a method for treating substance abuse comprising administering an effective amount of olanzapine or pharmaceutically acceptable salt thereof to a patient in need thereof.... | 12/12/2000 |
| 6143278 | Topical application of opioid analgesic drugs such as morphine The invention is directed to methods and pharmaceutical compositions for the topical administration of opioid analgesic drugs such as morphine. In particular, the invention relates to topical administration of an opioid analgesic agent, e.g., morphine sul... | 11/07/2000 |
| 6121259 | Olanzapine-N-oxide compositions and methods Methods and compositions are disclosed utilizing olanzapine-N-oxide for the treatment of psychosis in humans. Olanzapine-N-oxide exhibits a lessened liability toward drug-drug interactions than olanzapine and a more predictable dosing regimen than olanzap... | 09/19/2000 |
| 6103703 | Cytidine-containing and cytosine-containing compounds as treatments for stimulant exposure Disclosed herein is a method for reducing stimulant dependencies in mammals that involves administration of a therapeutically-effective amount of a cytosine-containing or cytidine-containing compound, such as CDP-choline.... | 08/15/2000 |
